Effect of RANKL Inhibition on UV-induced Immunosuppression

Trial Profile

Effect of RANKL Inhibition on UV-induced Immunosuppression

Phase of Trial: Phase I

Latest Information Update: 11 Aug 2014

At a glance

  • Drugs Denosumab (Primary)
  • Indications Immunosuppression; Skin cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top